Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
Kévin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, C. Gaultier, Sylvie Courtois, Nicolas Collongues, J. de Sèze
Topics & Concepts
FingolimodNatalizumabMedicineOcrelizumabMultiple sclerosisHazard ratioInternal medicineConfidence intervalImmunologyRituximabLymphomaMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersPolyomavirus and related diseases